
After being approved by the US Food and Drug Administration (FDA), there is a good chance that Biogen's Alzheimer's drug will also be approved in Europe, Sydbank Senior Analyst Søren Løntoft Hansen says.
The FDA has approved Biogen's Alzeheimer's treatment Aduhelm for use in the US, but it has not been approved in Europe, though there is a good chance this will happen, says Løntoft Hansen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app